Evotec SE (EVO) Noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions PR...

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction PR...

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader in DNA-encoded library (DEL...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical...

EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS

EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG...